AMSTERDAM, November 30 /PRNewswire-FirstCall/ -- Elsevier, the world's leading publisher of scientific, medical and technical products and services, today announced a major re-launch of Embase, its comprehensive biomedical database which holds over 20 million indexed records from more than 7,000 active, peer reviewed journals. Embase has long played a key role in the advancement of new biomedical and pharmaceutical insights. Now, new developments and updates include: - Enabling all biomedical researchers to use Embase -- extending its "usability" from information specialists to also include all biomedical and pharmaceutical scientists, and clinical and regulatory professionals. - New retrieval tools that further drive discovery, including quick and easy refining of search results and the display of indexed drug-drug and drug-disease relations. - Improved comprehensiveness through the addition of indexed articles-in-press and conference abstracts. - To signify the enhanced focus on biomedical answers, the product has a new, fresh look and feel to it. Thomas Gutjahr, Head of the Knowledge Center at Actelion Pharmaceuticals Ltd., comments: "I'm very impressed by all the new improvements which I believe will greatly help with pin-pointing certain searches, e.g. drug-drug interactions or drug-disease searches." Embase supports researchers with key tasks such as tracking of drug adverse events, comparing drug therapies, and Evidence Based Medicine research. It provides researchers with deep insights and understanding from the world's life sciences information, enabling effective discoveries towards medical discovery and treatment. ABOUT ELSEVIER Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com/) and Cell (http://www.cell.com/), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (http://www.sciencedirect.com/), Scopus (http://www.scopus.com/), Reaxys (http://www.reaxys.com/), MD Consult (http://www.mdconsult.com/) and Nursing Consult (http://www.nursingconsult.com/), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com/) and MEDai's Pinpoint Review (http://www.medai.com/), which help research and health care institutions deliver better outcomes more cost-effectively. A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com/) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com/), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). Media Contacts: Tom Reller Elsevier +1-215-239-3508 Emma Potter Kaizo PR +44-20-3043-4191 DATASOURCE: Elsevier CONTACT: Media Contacts: Tom Reller, Elsevier, +1-215-239-3508, ; Emma Potter, Kaizo PR, +44-20-3043-4191,

Copyright